JP2017501999A5 - - Google Patents

Download PDF

Info

Publication number
JP2017501999A5
JP2017501999A5 JP2016536910A JP2016536910A JP2017501999A5 JP 2017501999 A5 JP2017501999 A5 JP 2017501999A5 JP 2016536910 A JP2016536910 A JP 2016536910A JP 2016536910 A JP2016536910 A JP 2016536910A JP 2017501999 A5 JP2017501999 A5 JP 2017501999A5
Authority
JP
Japan
Prior art keywords
seq
ala
ser
pharmaceutical composition
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016536910A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017501999A (ja
JP6757667B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IL2014/051067 external-priority patent/WO2015083173A1/en
Publication of JP2017501999A publication Critical patent/JP2017501999A/ja
Publication of JP2017501999A5 publication Critical patent/JP2017501999A5/ja
Application granted granted Critical
Publication of JP6757667B2 publication Critical patent/JP6757667B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016536910A 2013-12-06 2014-12-07 Ｃｄ２８を介したシグナル伝達を阻害する短ペプチドによる炎症性疾病の症候の軽減 Expired - Fee Related JP6757667B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361912631P 2013-12-06 2013-12-06
US61/912,631 2013-12-06
US201461924869P 2014-01-08 2014-01-08
US61/924,869 2014-01-08
PCT/IL2014/051067 WO2015083173A1 (en) 2013-12-06 2014-12-07 Reduction of inflammatory disease symptoms by short peptides that inhibit signaling through cd28

Publications (3)

Publication Number Publication Date
JP2017501999A JP2017501999A (ja) 2017-01-19
JP2017501999A5 true JP2017501999A5 (https=) 2017-12-28
JP6757667B2 JP6757667B2 (ja) 2020-09-23

Family

ID=52396781

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016536910A Expired - Fee Related JP6757667B2 (ja) 2013-12-06 2014-12-07 Ｃｄ２８を介したシグナル伝達を阻害する短ペプチドによる炎症性疾病の症候の軽減

Country Status (7)

Country Link
US (2) US9963497B2 (https=)
EP (1) EP3077415B1 (https=)
JP (1) JP6757667B2 (https=)
AU (2) AU2014358677A1 (https=)
CA (1) CA2932150A1 (https=)
SG (2) SG10201804750XA (https=)
WO (1) WO2015083173A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3077415B1 (en) * 2013-12-06 2020-02-12 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Reduction of inflammatory disease symptoms by short peptides that inhibit signaling through cd28
WO2018195339A1 (en) 2017-04-19 2018-10-25 Board Of Regents, The University Of Texas System Immune cells expressing engineered antigen receptors
CN111163792A (zh) 2017-10-06 2020-05-15 耶路撒冷希伯来大学伊森姆研究发展有限公司 用于治疗病毒感染的肽
JP7273421B2 (ja) 2018-02-21 2023-05-15 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム ナチュラルキラー細胞の活性化および拡大のための方法ならびにその使用
CN111253469B (zh) * 2020-03-06 2021-09-07 暨南大学 一种自组装短肽及其在治疗痤疮方面的应用
WO2023080790A1 (en) * 2021-11-02 2023-05-11 Tosoj As Tri-, tetra and pentapeptides, compositions thereof and their use in the therapy of psoriasis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8535672B2 (en) * 2002-04-04 2013-09-17 Yissum Research Development Of The Hebrew University Of Jerusalem Broad-spectrum in-vivo effective superantigen toxin antagonists based on the interaction between CD28 and the superantigen and uses thereof
AU2003272065A1 (en) 2003-04-03 2004-10-25 Yissum Research Development Company Of The Hebrew University Of Jerusalem Broad-spectrum in-vivo effective superantigen toxin antagonists based on the interaction between cd28 and the superantigen and uses thereof
US20110097339A1 (en) * 2008-07-18 2011-04-28 Domantis Limited Compositions monovalent for CD28 binding and methods of use
EP2536764B1 (en) * 2010-02-18 2018-07-04 OSE Immunotherapeutics Anti-cd28 humanized antibodies
DE102012008730A1 (de) 2011-12-02 2013-06-06 Dr. Budz GmbH Orale Zusammensetzungen mit ungesättigten C18-Fettsäuren und ihre Verwendung
CA2860460A1 (en) 2012-01-16 2013-07-25 Atox Bio Ltd. Use of synthetic p2ta peptides in the treatment of ongoing bacterial infection and associated inflammation
EP3077415B1 (en) * 2013-12-06 2020-02-12 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Reduction of inflammatory disease symptoms by short peptides that inhibit signaling through cd28

Similar Documents

Publication Publication Date Title
JP2017501999A5 (https=)
US12297205B2 (en) Macrocyclic compounds for treatment of medical disorders
JP2015517489A5 (https=)
US20230021168A1 (en) Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors
JP2014501712A5 (https=)
JP2013543853A5 (https=)
JP2014511844A5 (https=)
JP2014529629A5 (https=)
TW200831533A (en) Interleukin-13 binding proteins
JP2009539349A5 (https=)
JP2014513953A5 (https=)
RU2017134274A (ru) Связывающие tslp белки
JP2007526208A (ja) 呼吸器の症状を治療又は予防する方法
JP2013517307A5 (https=)
JP2011528332A5 (https=)
BR112021004052A2 (pt) amidas de dimetil-amino azetidina como inibidores de jak
EP2568999A2 (en) Acth for treatment of amyotrophic lateral sclerosis
JP2020521458A5 (https=)
JP2012508698A5 (https=)
JP2011518857A5 (https=)
JP2021536510A (ja) 医学的障害の治療のための大環状化合物
JP2018538309A5 (https=)
JP2017524675A5 (https=)
JP2014520764A5 (https=)
JP2013542196A5 (https=)